Company Overview of Valent BioSciences Corporation
Valent BioSciences Corporation discovers, develops, manufactures, and commercializes biorational products for agriculture, public health, forestry, and household markets. The company offers microbial insecticides, nematicides, and plant growth regulators that are used in agricultural production for managing plant growth, quality, and stress in crops. It sells its products through a sales network in the United States, Canada, Mexico, Central/South America, Europe/the Middle East, Africa, South Africa, India, West Asia, East Asia, Japan, Australia, and New Zealand. Valent BioSciences Corporation has strategic alliances with Biomar Microbial Technologies and Rizobacter Argentina S.A. The compan...
870 Technology Way
Libertyville, IL 60048
Founded in 1999
Key Executives for Valent BioSciences Corporation
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President
Vice President of Global Research & Development and Regulatory Affairs
Vice President of Global Supply Chain & Manufacturing
Vice President of Global Marketing & Business Management
Compensation as of Fiscal Year 2017.
Valent BioSciences Corporation Key Developments
Valent BioSciences Corporation and the Donald Danforth Plant Science Center Announce the Finalization of Master Cooperation Agreement in the Area of Root Science and the Rhizosphere
Jul 14 16
Valent BioSciences Corporation and the Donald Danforth Plant Science Center announced the finalization of a multi-year, Master Cooperation Agreement in the area of root science and the rhizosphere. The agreement is designed to maximize outcome potential by intersecting core competencies from within the two organizations. The Danforth Center focuses on discoveries and technologies for improving agricultural productivity with minimal environmental impact including new research on non-destructive imaging technology for root growth dynamics. Over the last two years, VBC has made sizeable commitments to rhizosphere technologies including the acquisition of Mycorrhizal Applications, LLC (MA) and several licensing and research agreements designed to accelerate its root zone portfolio.
Valent Biosciences Corporation Signs Licensing Agreement with LidoChem and Rizobacter
Apr 26 16
Sumitomo Chemical announced that its wholly owned U.S. subsidiary Valent BioSciences Corporation has signed a global licensing agreement with a U.S. based company, LidoChem and a long-term development and commercialization cooperation agreement with an Argentina based company, Rizobacter, both aiming to strengthen its Biorational business further. With the global business matrix structure now established, Sumitomo Chemical Group is accelerating research and development activities, aiming to provide unique and innovative solutions for agriculture. The new technologies that become available under the above two agreements will provide Sumitomo Chemical with a greater opportunity to satisfy market needs more swiftly and properly by capitalizing on the two technological disciplines of health and crop science, that is plant protection chemicals and biorationals, which will contribute to meeting the world's growing demand for a secured and stable supply of safer foods.
Valent Biosciences Corporation Announces Construction of New Biorational Research Center
Apr 18 16
Valent BioSciences Corporation (VBC) has announced plans to construct a new Biorational Research Center (BRC) as an expansion of its current presence in Libertyville, IL. Part of a larger scale R&D investment plan being employed by parent Sumitomo Chemical Company (SCC), the VBC project includes an approximately 65,000 square foot build-out for dedicated lab and office space and an additional 20,000 square feet of greenhouse space at Innovation Park. VBC becomes the first occupant at the new 1.2 million square foot multi-tenant facility in Lake County, IL, just north of Chicago. Construction of the BRC means VBC will exit its current site of research operations in nearby Long Grove, IL. The company expects all of its Research personnel to make the move. Phase I of the BRC project is scheduled to be completed in mid-2017 and involves a USD 22 million investment to bring VBC's chemistry, biology, microbiology, fermentation and formulations labs under one roof. A 10,000 square foot research greenhouse is also part of the Phase I plan. Phase II, slated for completion in 2019, involves the construction of additional space finishing at an estimated cost of USD 5 million. The construction will significantly increase VBC's lab space and greenhouse footprint.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|